Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its risperidone extended-release injectable suspension in four strengths (12.5 mg/vial, 25 mg/vial, 37.5 mg/vial, 50 mg/vial). The therapy references Janssen’s Risperdal Consta® and is indicated for schizophrenia and maintenance treatment of Bipolar I disorder. The approval grants 180-day exclusivity under the FDA’s Competitive Generic Therapy (CGT) designation, with commercial launch expected in Q4 2025.
Science Significance
This approval showcases the advancement of microsphere formulation technology for sustained drug release, a critical innovation for long-acting psychiatric treatments. By enabling less frequent dosing, risperidone extended-release injectable suspension supports better adherence and improved continuity of care in serious mental health conditions.
Regulatory Significance
The FDA’s decision highlights the impact of the CGT pathway in accelerating access to complex generics. By granting market exclusivity, the agency incentivizes companies like Amneal to invest in technically challenging formulations that improve competition and patient access in mental health therapeutics.
Business Significance
Advertisement
Amneal strengthens its position in the complex injectables market, leveraging its expertise in microsphere development and cold-chain manufacturing. With U.S. annual sales of risperidone extended-release injectables estimated at $194 million (IQVIA, July 2025), this launch represents a significant growth opportunity and aligns with Amneal’s long-term strategy to expand high-barrier, high-value products.
Patients’ Significance
For individuals living with schizophrenia or Bipolar I disorder, adherence to daily medication is often difficult, leading to relapse and hospitalization. Long-acting injectable formulations like Amneal’s risperidone suspension provide patients with greater treatment stability, reduce relapse risks, and may improve overall quality of life.
Policy Significance
This approval reinforces U.S. healthcare policy priorities of expanding affordable access to mental health therapies. By utilizing the CGT framework, policymakers and regulators encourage competition in areas of high unmet need, while balancing innovation and cost containment for payers and patients.
Transaction Highlights
Amneal Pharmaceuticals achieved a major regulatory milestone with the FDA approval of risperidone extended-release injectable suspension, available in four dosage strengths. The product has been granted 180-day CGT exclusivity, giving Amneal a competitive advantage in a nearly $200 million annual market. The company expects to launch in the fourth quarter of 2025, leveraging its advanced R&D and manufacturing capabilities. This approval not only expands Amneal’s complex injectables portfolio but also solidifies its leadership in the development of long-acting psychiatric treatments.
Source: Amneal Pharmaceuticals LLC Press Release
